• Investing
  • Stock
  • Economy
  • Editor’s Pick
Portfolio Performance Today
Economy

Don’t Listen to De-growthers — Economic Growth Is Healthy!  

by June 3, 2023
by June 3, 2023

With the pandemic and the rise of climate alarmism, attacks on economic growth have multiplied. An increasingly larger set of pundits, academics, and politicians now embrace some variants of de-growth. They tie economic growth to a variety of “bad” outcomes. One of those “bads” is the idea that economic growth is not yielding many fruits in terms of better health outcomes – generally captured in the all-encompassing statistic of life expectancy at birth.

To make this claim, they (sometimes unknowingly) rely on the “Preston Curve” – named after Samuel Preston in a famous article in Demography. To visualize the curve, imagine a graph where life expectancy is depicted on the vertical axis and income is depicted on the horizontal axis. The line that draws the relation between both variables shows that for each additional increment in income, the associated increase in life expectancy is less than the previous increment. This phenomenon reflects the law of diminishing marginal returns. However, once a certain point is reached, there are no gains to be had. The curve is essentially a flat line after that point. 

From this, the inference made by many de-growthers is that we do not need more income than a certain fixed level. Anything beyond that brings little fruits and many harms.

This is a bad inference, however, because they forget many things. The first is that when it was first drawn, back in the 1970s, there were few “exceptionally rich” countries to draw the Preston Curve. Today there are far more countries that are exceptionally wealthy as seen from the vantage point of the 1970s. Over time, the curve has moved up and right. This means that not only is each dollar now more effective at improving health than before, but each additional dollar is more effective than it was before. True, the effect of an additional dollar is less than the effect of the previous dollar of income, but the effect remains positive. As such, de-growthers are understating the fruits of economic growth.

Second, and far more importantly, the curve’s shape is somewhat unsurprising because of biological considerations. Indeed, a large number of deaths in low-income countries are tied to preventable diseases and malnutrition. The role of a “natural” boundary to life expectancy matters little in these situations. As such, extra income (which allows for better nutrition, better water quality, better health care, and the like) makes it easy to improve life expectancy when it is “below” the biological boundary. Once one is closer to the boundary, improvements are harder to secure. At least, they are harder to secure unless one pushes the boundary further. And yet, pushing back that boundary is exactly what economic growth allows. In a recent article in Economics & Human Biology, economic historian Leandro Prados de la Escosura pointed out that it is far more impressive to improve life expectancy by one extra year when the statistic stands at 85 years rather than at 45 years. This means that we should give more “weight” to an extra year near the top rather than an extra year closer to the bottom. When this is done, we observe a totally different Preston Curve. Rather than seeing diminishing marginal returns, we see increasing ones!

Figure 1: The Preston Curve when we adjust for Biological Limits
Source: de la Escosura, L. P. (2023). Health, income, and the Preston curve: A long view. Economics & Human Biology, 48, 101212.

Why would economic growth allow us to push the biological boundary in a way that explains de la Escosura’s finding? Consider, for example, the role of research and development (R&D) in biopharmaceuticals which explains a sizable share of the gains of gains in life expectancy at age 50, 60 and 65. That R&D is long and it is also immensely costly. Poor societies can ill-afford to spend time and resources on this type of activities. This is why we observe that R&D as a share of total gross domestic product increases is higher in richer countries than in poorer ones. Richer societies can dedicate resources more easily to pushing biological boundaries through R&D.

This means that there are no diminishing effects of income on our ability to secure equally difficult improvements in health outcomes. The wealthier we are, the easier it is to tackle the “hard” health issues.  The de-growthers could not be more wrong – growth is healthy!

0 comment
0
FacebookTwitterPinterestEmail

previous post
Before Joining the Boycott Bandwagon, Consider This
next post
Anarchy and Bitcoin

Related Posts

An Insider Untangles the Causes of the Financial...

October 1, 2023

Why is Baby Formula Kept Under Lock and...

September 30, 2023

Inflation was Worse than We Thought

September 30, 2023

Reaching Across the Aisle for the Bill of...

September 29, 2023

Is America Today Less Able Than In the...

September 29, 2023

How Crazy Do You Have to Be to...

September 28, 2023

Wishful (Protectionist) Thinking 

September 28, 2023

Weighing Whether the Standard Scale Makes Sense

September 27, 2023

Eyes, Shoulders, Knees, and Toes: Rebutting Robert Gordon’s...

September 27, 2023

What Should the Federal Reserve Do Now?

September 26, 2023

Recent Posts

  • An Insider Untangles the Causes of the Financial Crisis in American Cities

    October 1, 2023
  • TSR Market Update: Bluetooth Low Energy Market

    October 1, 2023
  • Everynet Announces General Availability of LoRaWAN Connectivity Using AWS IoT Core for LoRaWAN

    October 1, 2023
  • Why is Baby Formula Kept Under Lock and Key?

    September 30, 2023
  • Inflation was Worse than We Thought

    September 30, 2023
  • Let’s Stop Pretending IoT Is Easy

    September 29, 2023

Editors’ Picks

  • 1

    Nvidia Corporation earnings beat not sufficient to boost stock – Is it a good buy?

    February 18, 2022
  • 2

    2 Canadian marijuana stocks to keep a close eye on

    February 5, 2022
  • 3

    Is it too late to sell Biogen stock after losing an appeal on its multiple sclerosis drug?

    November 30, 2021
  • 4

    Headed for Insolvency: Biden Administration Increases US Obligations Worldwide

    May 29, 2022
  • 5

    The General Welfare

    November 4, 2021
  • 6

    The IMF Should Be Eliminated, Not Expanded

    October 12, 2021
  • 7

    Micron Technology shares are trading lower after-hours: here’s why

    September 29, 2021
Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Categories

  • Economy (2,131)
  • Editor's Pick (727)
  • Investing (5,549)
  • Stock (10)
About Us Terms & Conditions Privacy Policy Email WhiteListing Contact Us

Disclaimer: Portfolioperformancetoday.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2023 Portfolioperformancetoday.com All Rights Reserved.

Portfolio Performance Today
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
Portfolio Performance Today
  • Investing
  • Stock
  • Economy
  • Editor’s Pick

Read alsox

G.K. Chesterton on the Fundamentals of Liberalism

September 27, 2022

How Arrogance Threatens Freedom

May 24, 2023

Energy Hypocrisy as Rich Countries Denying the...

August 11, 2022